This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (26)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Aging/ Geriatrics  • Venous Thromboembolism  • Adverse Effects  • Alert me on articles by topic

Marieke Torn, MD; Ward L. E. M. Bollen, MD; Felix J. M. van der Meer, MD; Ernst E. van der Wall, MD; Frits R. Rosendaal, MD

Arch Intern Med. 2005;165:1527-1532.

Background  Oral anticoagulation in the elderly is a dilemma. Although many elderly patients have strict indications for treatment with coumarin derivatives, the tendency toward an increased bleeding risk with age is a matter of concern. We investigated the risk of hemorrhage and thromboembolism according to age in patients who were treated with oral anticoagulants in the routine setting of an anticoagulation clinic.

Methods  All patients of the Leiden Anticoagulation Clinic (Leiden, the Netherlands) who were treated because of mechanical heart valve prostheses (target, international normalized ratio [INR] of 3.5), atrial fibrillation (target, INR of 3.0), or after a myocardial infarction (target, INR of 3.0) between 1994 and 1998 were included in the study and grouped by age at the start of follow-up. We calculated incidence rates of major hemorrhage and thromboembolism per age group.

Results  We included 4202 patients: 842 patients younger than 60 years; 1200 patients aged between 60 and 70 years; 1464 patients aged between 71 and 80 years; and 696 patients older than 80 years. The incidence rate of major hemorrhage rose gradually with age from 1.5 per 100 patient-years for patients younger than 60 years to 4.2 per 100 patient-years for patients older than 80 years, yielding a hazard ratio of 2.7 (95% confidence interval, 1.7-4.4). The incidence rate of major thromboembolism rose from 1.0 per 100 patient-years for patients younger than 60 years to 2.4 per 100 patient-years for patients older than 80 years (hazard ratio, 2.2; 95% confidence interval, 1.2-4.2).

Conclusions  The incidence of both bleeding and thromboembolic events increases sharply with advanced age. Because higher thromboembolic risk with age often makes it unfeasible to withhold oral anticoagulation from elderly patients, future studies should focus on ways to lower the bleeding risk.

Author Affiliations: Departments of Hematology (Drs Torn, van der Meer, and Rosendaal), Neurology (Dr Bollen), Cardiology (Dr van der Wall), and Clinical Epidemiology (Dr Rosendaal), Leiden University Medical Center, Leiden Anticoagulation Clinic (Dr van der Meer), Leiden, the Netherlands.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Ansell et al.
Chest 2008;133:160S-198S.
ABSTRACT | FULL TEXT  

Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Singer et al.
Chest 2008;133:546S-592S.
ABSTRACT | FULL TEXT  

Valvular and Structural Heart Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Salem et al.
Chest 2008;133:593S-629S.
ABSTRACT | FULL TEXT  

Anticoagulation for elderly patients with atrial fibrillation: not to be neglected
Taggar and Lip
Europace 2008;10:1-2.
FULL TEXT  

Self-Management of Oral Anticoagulation Therapy Improves Long-Term Survival in Patients With Mechanical Heart Valve Replacement
Koertke et al.
Ann. Thorac. Surg. 2007;83:24-29.
ABSTRACT | FULL TEXT  

Anticoagulation in ischaemic heart disease.
De Cristofaro
Heart 2006;92:1011-1012.
FULL TEXT